Special Issue

Toward a New Era in the Management of Hepatocellular Carcinoma: Novel Perspective on Therapeutic Options and Biomarkers

Message from the Guest Editors

For over a decade, the TKI inhibitor sorafenib represented the main therapeutic option for the treatment of advanced Hepatocellular carcinoma (HCC). In the last few years, new therapies have been approved as first- and/or second-line treatments, including immunotherapeutic agents, which have also shown promising results. Despite these improvements in the pharmacological treatment of HCC, its prognosis remains poor, and the overall survival of patients remains short. In this scenario, many efforts have been and are currently directed to the identification of novel pharmacological targets that could be exploited by new candidate drugs, and the evaluation of combination therapy strategies. The identification of novel biomarkers for early diagnosis and/or as prognostic indicators of responses to treatments will also significantly improve our knowledge about HCC. This Special Issue aims to provide new insights into novel molecular targets, therapeutic options, combination therapies, and/or biomarkers that could potentially be exploited for clinical development.

Guest Editors

Dr. Daniela Gabbia

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, L. go Meneghetti 2, 35131 Padova, Italy

Dr. Sara De Martin

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, L.go Meneghetti 2, 35131 Padova, Italy

Deadline for manuscript submissions

closed (31 October 2022)



International Journal of Molecular Sciences

an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 9.0 Indexed in PubMed



mdpi.com/si/99054

International Journal of Molecular Sciences Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 ijms@mdpi.com

mdpi.com/journal/ ijms





International Journal of Molecular Sciences

an Open Access Journal by MDPI

Impact Factor 4.9 CiteScore 9.0 Indexed in PubMed





Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biochimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

